Syringetin suppresses osteoclastogenesis mediated by osteoblasts in human lung adenocarcinoma

Tsai,Ying-Ming; Chong,Inn-Wen; Hung,Jen-Yu; Chang,Wei-An; Kuo,Po-Lin; Tsai,Ming-Ju; Hsu,Ya-Ling

doi:10.3892/or.2015.4028

Syringetin suppresses osteoclastogenesis mediated by osteoblasts in human lung adenocarcinoma

Authors:
- Ying-Ming Tsai
- Inn-Wen Chong
- Jen-Yu Hung
- Wei-An Chang
- Po-Lin Kuo
- Ming-Ju Tsai
- Ya-Ling Hsu
View Affiliations

Affiliations: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
Published online on: June 4, 2015 https://doi.org/10.3892/or.2015.4028
Pages: 617-626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone metastasis in lung cancer results in an unfavorable outcome for patients by not only impairing the quality of life, yet also increasing the cancer-related death rates. In the present study, we discuss a novel treatment strategy that may benefit these patients. Human CD14+ monocytes treated with macrophage-colony stimulating factor (M-CSF)/receptor activator of nuclear factor κB ligand (RANKL) differentiated into osteoclasts, whereas syringetin (SGN), a flavonoid derivative found in both grapes and wine, suppressed the osteoclastogenesis in vitro in a dose‑dependent manner. In addition, SGN inhibited osteoclast formation induced by human lung adenocarcinoma A549 and CL1-5 cells. The associated signaling transduction pathway in osteoclastogenesis and SGN inhibition was found to be via the AKT/mammalian target of rapamycin (mTOR) signaling pathway. Blocking AKT and mTOR by respective inhibitors significantly decreased lung adenocarcinoma-mediated osteoclastogenesis. Moreover, SGN regulated the lung adenocarcinoma-mediated interaction between osteoblasts and osteoclasts by suppressing the stimulatory effect of lung adenocarcinoma on M-CSF and RANKL production in osteoblasts, and reversing the inhibitory effect of the lung adenocarcinoma on OPG production in osteoblasts. The present study has two novel findings. It is the first to illustrate lung adenocarcinoma-mediated interaction between osteoblasts and osteoclasts, leading to osteolytic bone metastasis. It also reveals that SGN, a flavonoid derivative, directly inhibits osteoclastogenesis and reverses lung adenocarcinoma‑mediated osteoclastogenesis. In conclusion, the present study suggests that SGN, a natural compound, prevents and treats bone metastasis in patients with lung cancer.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zükin M: Epidermal growth factor receptor inhibitors in non-small cell lung cancer: Current status and future perspectives. Rev Assoc Med Bras. 58:263–268. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kuo PL, Liao SH, Hung JY, Huang MS and Hsu YL: MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta. 1830:3756–3766. 2013. View Article : Google Scholar : PubMed/NCBI
4	Al Husaini H, Wheatley-Price P, Clemons M and Shepherd FA: Prevention and management of bone metastases in lung cancer: A review. J Thorac Oncol. 4:251–259. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE and Coleman RE: Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 3:228–236. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sterling JA, Edwards JR, Martin TJ and Mundy GR: Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. Bone. 48:6–15. 2011. View Article : Google Scholar
7	Sims NA and Gooi JH: Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 19:444–451. 2008. View Article : Google Scholar : PubMed/NCBI
8	Miller RE, Jones JC, Tometsko M, Blake ML and Dougall WC: RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol. 9:345–354. 2014. View Article : Google Scholar : PubMed/NCBI
9	Pawelek JM and Chakraborty AK: The cancer cell - leukocyte fusion theory of metastasis. Adv Cancer Res. 101:397–444. 2008. View Article : Google Scholar
10	Roato I: Interaction among cells of bone, immune system, and solid tumors leads to bone metastases. Clin Dev Immunol. 2013:3150242013. View Article : Google Scholar : PubMed/NCBI
11	Burger JA and Stewart DJ: CXCR4 chemokine receptor antagonists: Perspectives in SCLC. Expert Opin Investig Drugs. 18:481–490. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hsieh CJ, Kuo PL, Hou MF, Hung JY, Chang FR, Hsu YC, Huang YF, Tsai EM and Hsu YL: Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling. Int J Oncol. 46:555–562. 2015.
13	Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q and Zhang J: Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia. 11:228–236. 2009. View Article : Google Scholar : PubMed/NCBI
14	Takiguchi S, Korenaga N, Inoue K, Sugi E, Kataoka Y, Matsusue K, Futagami K, Li YJ, Kukita T, Teramoto N, et al: Involvement of CXCL14 in osteolytic bone metastasis from lung cancer. Int J Oncol. 44:1316–1324. 2014.PubMed/NCBI
15	Hsu YL, Hung JY, Ko YC, Hung CH, Huang MS and Kuo PL: Phospholipase D signaling pathway is involved in lung cancer-derived IL-8 increased osteoclastogenesis. Carcinogenesis. 31:587–596. 2010. View Article : Google Scholar : PubMed/NCBI
16	Flamini R, Mattivi F, De Rosso M, Arapitsas P and Bavaresco L: Advanced knowledge of three important classes of grape phenolics: Anthocyanins, stilbenes and flavonols. Int J Mol Sci. 14:19651–19669. 2013. View Article : Google Scholar : PubMed/NCBI
17	Rimando AM, Kalt W, Magee JB, Dewey J and Ballington JR: Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem. 52:4713–4719. 2004. View Article : Google Scholar : PubMed/NCBI
18	Pan MH, Chang YH, Tsai ML, Lai CS, Ho SY, Badmaev V and Ho CT: Pterostilbene suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages. J Agric Food Chem. 56:7502–7509. 2008. View Article : Google Scholar : PubMed/NCBI
19	Pan MH, Chang YH, Badmaev V, Nagabhushanam K and Ho CT: Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells. J Agric Food Chem. 55:7777–7785. 2007. View Article : Google Scholar : PubMed/NCBI
20	Pan MH, Chiou YS, Chen WJ, Wang JM, Badmaev V and Ho CT: Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis. 30:1234–1242. 2009. View Article : Google Scholar : PubMed/NCBI
21	Pan MH, Lin YT, Lin CL, Wei CS, Ho CT and Chen WJ: Suppression of heregulin-β1/HER2-modulated invasive and aggressive phenotype of breast carcinoma by pterostilbene via inhibition of matrix metalloproteinase-9, p38 kinase cascade and Akt activation. Evid Based Complement Alternat Med. 2011:5621872011. View Article : Google Scholar
22	Chiou YS, Tsai ML, Wang YJ, Cheng AC, Lai WM, Badmaev V, Ho CT and Pan MH: Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J Agric Food Chem. 58:8833–8841. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chiou YS, Tsai ML, Nagabhushanam K, Wang YJ, Wu CH, Ho CT and Pan MH: Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J Agric Food Chem. 59:2725–2733. 2011. View Article : Google Scholar : PubMed/NCBI
24	Chen RJ, Tsai SJ, Ho CT, Pan MH, Ho YS, Wu CH and Wang YJ: Chemopreventive effects of pterostilbene on urethane-induced lung carcinogenesis in mice via the inhibition of EGFR-mediated pathways and the induction of apoptosis and autophagy. J Agric Food Chem. 60:11533–11541. 2012. View Article : Google Scholar : PubMed/NCBI
25	Mühlbauer RC, Lozano A, Reinli A and Wetli H: Various selected vegetables, fruits, mushrooms and red wine residue inhibit bone resorption in rats. J Nutr. 133:3592–3597. 2003.PubMed/NCBI
26	Singh H, Dixit S, Verma PC and Singh PK: Evaluation of total phenolic compounds and insecticidal and antioxidant activities of tomato hairy root extract. J Agric Food Chem. 62:2588–2594. 2014. View Article : Google Scholar : PubMed/NCBI
27	Mattivi F, Guzzon R, Vrhovsek U, Stefanini M and Velasco R: Metabolite profiling of grape: Flavonols and anthocyanins. J Agric Food Chem. 54:7692–7702. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wang H, Race EJ and Shrikhande AJ: Anthocyanin transformation in Cabernet Sauvignon wine during aging. J Agric Food Chem. 51:7989–7994. 2003. View Article : Google Scholar : PubMed/NCBI
29	Castillo-Muñoz N, Gómez-Alonso S, García-Romero E and Hermosín-Gutiérrez I: Flavonol profiles of Vitis vinifera red grapes and their single-cultivar wines. J Agric Food Chem. 55:992–1002. 2007. View Article : Google Scholar : PubMed/NCBI
30	Castillo-Muñoz N, Gómez-Alonso S, García-Romero E, Gómez MV, Velders AH and Hermosín-Gutiérrez I: Flavonol 3-O-glycosides series of Vitis vinifera Cv. Petit Verdot red wine grapes. J Agric Food Chem. 57:209–219. 2009. View Article : Google Scholar
31	Gómez-Alonso S, Collins VJ, Vauzour D, Rodríguez-Mateos A, Corona G and Spencer JPE: Inhibition of colon adenocarcinoma cell proliferation by flavonols is linked to a G2/M cell cycle block and reduction in cyclin D1 expression. Food Chem. 130:493–500. 2012. View Article : Google Scholar
32	Hsu YL, Liang HL, Hung CH and Kuo PL: Syringetin, a flavonoid derivative in grape and wine, induces human osteoblast differentiation through bone morphogenetic protein-2/extracellular signal-regulated kinase 1/2 pathway. Mol Nutr Food Res. 53:1452–1461. 2009. View Article : Google Scholar : PubMed/NCBI
33	Chen HW, Lee JY, Huang JY, Wang CC, Chen WJ, Su SF, Huang CW, Ho CC, Chen JJ, Tsai MF, et al: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 68:7428–7438. 2008. View Article : Google Scholar : PubMed/NCBI
34	Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R and Wu CW: Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 17:353–360. 1997. View Article : Google Scholar : PubMed/NCBI
35	Sambandam Y, Sundaram K, Liu A, Kirkwood KL, Ries WL and Reddy SV: CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene. 32:97–105. 2013. View Article : Google Scholar
36	Wu X, Liu T, Fang O, Leach LJ, Hu X and Luo Z: miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27^kip1. Oncogene. 33:1506–1514. 2014. View Article : Google Scholar
37	Hernández I, Moreno JL, Zandueta C, Montuenga L and Lecanda F: Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene. 29:3758–3769. 2010. View Article : Google Scholar : PubMed/NCBI
38	Sone S and Yano S: Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev. 26:685–689. 2007. View Article : Google Scholar : PubMed/NCBI
39	Weilbaecher KN, Guise TA and McCauley LK: Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425. 2011. View Article : Google Scholar : PubMed/NCBI
40	Coleman RE and McCloskey EV: Bisphosphonates in oncology. Bone. 49:71–76. 2011. View Article : Google Scholar : PubMed/NCBI
41	Furugaki K, Moriya Y, Iwai T, Yorozu K, Yanagisawa M, Kondoh K, Fujimoto-Ohuchi K and Mori K: Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis. 28:649–659. 2011. View Article : Google Scholar : PubMed/NCBI
42	Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY and Kuo PL: Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem. 286:37335–37346. 2011. View Article : Google Scholar : PubMed/NCBI
43	Takayanagi H: New immune connections in osteoclast formation. Ann NY Acad Sci. 1192:117–123. 2010. View Article : Google Scholar : PubMed/NCBI
44	Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G and Terpos E: Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 46:221–229. 2007. View Article : Google Scholar : PubMed/NCBI
45	McGrath EE: OPG/RANKL/RANK pathway as a therapeutic target in cancer. J Thorac Oncol. 6:1468–1473. 2011. View Article : Google Scholar : PubMed/NCBI
46	Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, Nogueira V, Hahn-Windgassen A, Kiyokawa H and Hay N: Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 10:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
47	Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY and Kim N: Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J Immunol. 188:163–169. 2012. View Article : Google Scholar
48	Cao H, Zhu K, Qiu L, Li S, Niu H, Hao M, Yang S, Zhao Z, Lai Y, Anderson JL, et al: Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem. 288:30399–30410. 2013. View Article : Google Scholar : PubMed/NCBI
49	Sugatani T and Hruska KA: Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 280:3583–3589. 2005. View Article : Google Scholar
50	Sanchez CP and He YZ: Bone growth during rapamycin therapy in young rats. BMC Pediatr. 9:32009. View Article : Google Scholar : PubMed/NCBI